| |
|
|
|
Xtalks, online
2022 -10-27
Neurofilament light chain (NfL) protein has been well studied in a broad array of neurodegenerative diseases for years, and yet the specific parameters of its use in clinical settings have not yet been well established. Recently, Labcorp made NfL widely available as an orderable lab test for clinicians nationwide, but its prior unavailability has left questions about how it can be practically employed in patient workups and monitoring. Still, clinicians are beginning to use NfL and are learning about how it can provide useful and important information for patient care.
Register to understand what neurofilament light chain is and its importance in neurology, and ways that it may be practically used in patients with multiple sclerosis, concussion and amyotrophic lateral sclerosis (ALS).
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Dr. Michelle Mielke, PhD, Professor, Epidemiology and Prevention, Wake Forest University School of Medicine Dr. Nicholas Streicher, MD, MPH, MedStar Washington Hospital Center Dr. Asya Wallach, MD, MS Center Physician, Holy Name Medical Center (Moderator) Dr. Joe Volpe, PhD, Scientific Discipline Director, Labcorp
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2022 -10-27
|
|
|
|
|
|
|
|
Registration:
|
|
Free registration
|
|
|
E-mail:
|
|
ajuurinen@xtalks.com
|
|
|
|
|
|
|
|
|